Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
Andrea Casadei‐Gardini, Lorenza Rimassa, Margherita Rimini, Changhoon Yoo, Baek‐Yeol Ryoo, Sara Lonardi, Gianluca Masi, Hyung‐Don Kim, Caterina Vivaldi, Min‐Hee Ryu, Mario Domenico Rizzato, Francesca Salani, Yeonghak Bang, Antonio Pellino, Silvia Catanese, Valentina Burgio, Stefano Cascinu, Alessandro Cucchetti
Topics & Concepts
RegorafenibSorafenibCabozantinibMedicineInternal medicineHepatocellular carcinomaPlaceboSubgroup analysisOncologyGastroenterologyConfidence intervalCancerColorectal cancerPathologyAlternative medicineHepatocellular Carcinoma Treatment and PrognosisCancer Mechanisms and TherapyCholangiocarcinoma and Gallbladder Cancer Studies